Highlights
-
Recent advances in biomedical applications of metal–organic framework (MOF) nanocarriers for drug delivery are summarized.
-
State-of-the-art strategies to functionalize MOFs with therapeutic agents, as well as their merits and drawbacks, are comprehensively discussed.
Abstract
Investigation of metal–organic frameworks (MOFs) for biomedical applications has attracted much attention in recent years. MOFs are regarded as a promising class of nanocarriers for drug delivery owing to well-defined structure, ultrahigh surface area and porosity, tunable pore size, and easy chemical functionalization. In this review, the unique properties of MOFs and their advantages as nanocarriers for drug delivery in biomedical applications were discussed in the first section. Then, state-of-the-art strategies to functionalize MOFs with therapeutic agents were summarized, including surface adsorption, pore encapsulation, covalent binding, and functional molecules as building blocks. In the third section, the most recent biological applications of MOFs for intracellular delivery of drugs, proteins, and nucleic acids, especially aptamers, were presented. Finally, challenges and prospects were comprehensively discussed to provide context for future development of MOFs as efficient drug delivery systems.
![](http://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40820-020-00423-3/MediaObjects/40820_2020_423_Figa_HTML.png)
Similar content being viewed by others
Avoid common mistakes on your manuscript.
1 Introduction
Metal–organic frameworks (MOFs) represent a promising class of highly ordered crystalline porous coordination polymers (PCPs) [1,2,3]. The extended infinite one-/two-/three-dimensional networks of MOFs are formed by the linkage of inorganic metal (e.g., transition metal and lanthanide metal) ions/clusters as the node and organic ligands (e.g., carboxylates, phosphonates, imidazolates, and phenolates) as the strut. In 1995, the Yaghi group studied selective binding and removal of guest molecules in a microporous MOF composed of 1,3,5-benzenetricarboxylate (BTC) and cobalt cation [4]. In 1999, the same group reported the design and synthesis of MOF-5, which contains 1,4-benzenedicarboxylate (BDC) and Zn4O clusters [5]. MOF-5 showed exceptionally high Langmuir surface area of 2900 m2 g−1. Over the past two decades, owing to extremely high surface area and pore volume, as well as tunable pore size and chemical composition, MOFs have been studied for various applications, including, for example, gas storage and separation [6,7,8,9], chemical separation [10b). The pEGFP-C1@ZIF-8-PEI 25 kD nanoparticles showed a higher transfection efficacy (above 10%) in every dosage. These results were also confirmed by the confocal images (Fig. 10c).
![figure 10](http://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40820-020-00423-3/MediaObjects/40820_2020_423_Fig10_HTML.png)
Reproduced with permission from Ref. [127]. Copyright 2019, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
a Schematic illustration of the synthesis of pEGFP-C1@ZIF-8 via biomimetic mineralization and pEGFP-C1@ZIF-8-polymer via co-precipitation followed by cellular delivery and expression. b Transfection efficacy of pEGFP-C1@ZIF-8, pEGFP-C1@ZIF-8-PEI 25 kD, and lipofectamine-2000 at different concentrations. c Representative CLSM images of pEGFP-C1 expression in MCF-7 cells.
Small interfering RNA (siRNA) was discovered in 1998, offering a new way to combat resistant cancers [128]. MOFs have been proved as effective nanocarriers for siRNA delivery to protect it against clearance or degradation before taking effect in the target cells. The Lin group reported the first use of MOF nanocarriers for the co-delivery of cisplatin and pooled siRNAs to enhance chemotherapeutic efficacy in drug-resistant ovarian cancer cells (SKOV-3 cells) [129]. siRNA was loaded on the surface of UiO-type Zr-MOF nanoparticles through coordination to Zr6 clusters with high loading efficiency (81.6%), while cisplatin prodrug was efficiently encapsulated into the MOF nanoparticles (12.3 wt%). Studies demonstrated the advantages of utilizing MOF nanocarriers to protect siRNAs from nuclease degradation, increase siRNA cellular uptake, and promote siRNA escape from endosomes to silence multidrug resistance genes. Therefore, an order-of-magnitude enhancement of chemotherapeutic efficacy of cisplatin was achieved. Similarly, the Liu group reported the synthesis of MIL-101(Fe) as the nanocarrier to co-deliver pooled siRNAs and selenium(Se)/ruthenium(Ru) nanoparticles to reverse multidrug resistance in Taxol-resistant breast cancer cells (Fig. 11a) [130]. The endosomal escape of siRNA was investigated by confocal laser scanning microscopy. After incubation for 3 h, most of the green fluorescence (siRNAFAM) and red fluorescence (lysosome tracker) in the cytoplasm were separated, suggesting the escape of siRNA from the entrapment of endo-/lysosome to accumulate in the cytoplasm (Fig. 11b). The gene transfection efficiency of Se@MIL-101 and Ru@MIL-101 was measured by EGFP transfection assay in MCF-7/T cells (Fig. 11c). The therapy efficacy was enhanced by the silencing of MDR genes and interference of microtubule (MT) dynamics in MCF-7/T cells. Moreover, high targeting specificity to tumor cells, increased antitumor efficacy, and reduced systemic toxicity in vivo were observed. These studies demonstrated the potential of MOF nanoparticles as a novel nanocarrier platform for co-delivery of chemotherapeutic agents and siRNAs to drug-resistant cancer cells.
![figure 11](http://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40820-020-00423-3/MediaObjects/40820_2020_423_Fig11_HTML.png)
Reproduced with permission from Ref. [130]. Copyright 2017, American Chemical Society
a Mechanism of Se/Ru nanoparticles and siRNA co-delivery by MIL-101 for the reversal of drug resistance and induced apoptosis by the disruption of microtubule in MCF-7/T (Taxol-resistant) cancer cells. b Time-dependent confocal microscopy of siRNA escaped from endosomes in MCF-7/T cells. Scale bar: 5 μm. c Fluorescence microscope images of MCF-7/T cells transfected by Se@MIL-101 and Ru@MIL-101 for 24 h.
Nucleic acid aptamers usually consist of short strands of oligonucleotides. These oligonucleotide molecules can be engineered to recognize and bind to specific molecular targets such as small molecules, proteins, and nucleic acids [131,132,133]. So far, various aptamers have been selected and widely used as effective molecular probes for cancer study based on their high binding specificity and sensitivity, ease of synthesis, improved storage, as well as lack of immunogenicity [134,135,136,137]. Particularly, the Tan group pioneered the whole-cell systematic evolution of ligands by exponential enrichment (cell-SELEX) approach for high-affinity aptamer selection [138,139,140,141,142]. This method allows for the selection of aptamers against specific cell lines to accelerate the discovery of biomarkers (Fig. 12). So far, the group has successfully selected a series of aptamers through the cell-SELEX method. For example, aptamers have been selected against leukemia [143], lung cancer [144], and cells infected with the Vacinia virus [145], as well as aptamers specific for phosphorylation epitopes of tau protein [146].
![figure 12](http://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40820-020-00423-3/MediaObjects/40820_2020_423_Fig12_HTML.png)
Reproduced with permission from Ref. [139]. Copyright 2009, American Chemical Society
Schematic representation of the cell-SELEX approach for aptamer selection.
With the development of aptamer selection for molecular medicine, MOF nanocarriers for aptamer delivery have been investigated during the last few years, taking advantage of the unique properties of aptamers. For instance, Fang and coworkers demonstrated that AS1411 aptamer-functionalized UiO-66@AgNCs@Apt can be internalized effectively by target cancer cells (MCF-7 cells) with high selectivity through AS1411-mediated endocytosis [147]. Upon one-pot incorporation of the anticancer drug DOX, this drug delivery system exhibited high capability for targeted delivery and intracellular controlled release, resulting in enhanced antitumor effect in vitro.
Several efforts have been made toward controlled release of drugs utilizing aptamer-functionalized MOF nanoparticles. This was achieved by designing MOFs responsive to different triggers, e.g., ATP and glucose. The Willner group modified the external surface of MOF nanoparticles (UiO-68) with ATP-AS1411 hybrid aptamer in caged configurations [148]. ATP is upregulated in cancer cells, while AS1411 aptamer identifies the nucleolin receptor sites on the cancer cell membrane. In the presence of ATP, the MOFs were unlocked by ATP–aptamer complex formation, releasing the loaded drug molecules (DOX). Experiments revealed high cytotoxic efficacy and highly selective permeation of these dual aptamer-modified MOF nanocarriers into MDA-MB-231 breast cancer cells as compared to MCF-10A normal epithelial breast cells. The group subsequently designed glucose-responsive MOF nanocarriers for controlled release of drugs [149]. ZIF-8 nanoparticles were loaded with glucose oxidase (GOx) and antivascular endothelial growth factor aptamer (VEGF aptamer). Upon GOx-mediated aerobic oxidation of glucose, the products gluconic acid and H2O2 acidified the microenvironment and caused pH-induced degradation of MOFs to release drugs (Fig. 13a). The VEGF aptamer could potentially inhibit angiogenic regeneration of blood vessels. The loadings of VEGF aptamer and GOx were confirmed by confocal microscopy imaging (Fig. 13b). Panels I and II suggested that the Cy3-modified VEGF aptamer (red) and the coumarin-functionalized GOx (blue) were successfully incorporated into ZIF-8. The Fan group reported immunostimulatory DNA–MOFs (isMOFs) containing cytosine–phosphate–guanosine (CpG) oligonucleotides, which exhibited high cellular uptake, organelle specificity, and spatiotemporal control of Toll-like receptors (TLR)-triggered immune responses [150].
![figure 13](http://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40820-020-00423-3/MediaObjects/40820_2020_423_Fig13_HTML.png)
Reproduced with permission from Ref. [149]. Copyright 2018, American Chemical Society
a Mechanism of glucose-driven release of VEGF aptamer from ZIF-8 caused by degradation of MOFs under local acidified conditions created by GOx-catalyzed aerobic oxidation of glucose to gluconic acid. b Confocal microscopy images of ZIF-8 loaded with Cy3-modified VEGF aptamer (I) and coumarin-functionalized GOx@ZIF-8 (II), and the bright field and merged image of the loaded MOF (III and IV, respectively).
3.3 Proteins
Proteins are macromolecules consisting of one or more long chains of amino acid residues. They serve a large number of functions, such as DNA replication, metabolic reaction catalysis, and molecular transport. Since proteins have large size, charged surface, and environmental sensitivity, it is difficult for proteins to naturally cross cell membranes without losing structural integrity. In order to utilize proteins for therapeutic purposes, MOF nanoparticles for intracellular delivery of proteins have attracted increasing attention in recent years.
For example, Farha et al. selected NU-1000 and PCN-222/MOF-545 nanoparticles as the host for insulin encapsulation [151]. The surface of MOFs was modified with phosphate-terminated nucleic acids for increased colloidal stability and cellular uptake. Compared to the native protein, a tenfold enhancement of cellular uptake was achieved. The Zheng group synthesized a pH-sensitive nanocomposite with a core–shell structure as the drug delivery system [152]. Biocompatible bovine serum albumin (BSA) and DOX (BSA/DOX) core was protected by the ZIF-8 shell. The BSA/DOX@ZIF-8 showed greater antitumor efficacy than that of free DOX against breast cancer cell line MCF-7.
Recently, Mao and coworkers have developed zeolitic imidazole framework-90 (ZIF-90) as a general platform to deliver different proteins into the cytosol, independent of their size and molecular weight [153]. Protein encapsulation was performed by self-assembly of imidazole-2-carboxaldehyde, Zn2+, and the protein (Fig. 14a). Degradation of nanoparticles to release protein was observed in the presence of ATP. HeLa cells were treated with ZIF-90/GFP nanoparticles for cellular uptake study. According to the flow cytometry analysis, the cellular uptake of ZIF-90/GFP increased proportionally with the concentration of GFP increasing from 40 to 100 μg mL−1 (Fig. 14b). Next, different endocytosis inhibitors were selected for pretreatment. Among them, only sucrose reduced the cellular uptake efficiency significantly (down to 17%) (Fig. 14c), indicating that ZIF-90/GFP is mainly internalized via clathrin-mediated endocytosis. After incubation of HeLa cells with 50 μg mL−1 ZIF90/GFP nanoparticles, a significant accumulation of GFP in the cytosol was observed by CLSM imaging (Fig. 14d). Furthermore, ZIF-90/protein nanoparticles were used to successfully deliver cytotoxic RNase A for tumor cell growth inhibition, as well as genome-editing protein Cas9 to knock out the green fluorescent protein (GFP) expression of HeLa cells.
![figure 14](http://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40820-020-00423-3/MediaObjects/40820_2020_423_Fig14_HTML.png)
Reproduced with permission from Ref. [153]. Copyright 2019, American Chemical Society
a Schematic illustration of the synthesis of ZIF-90/protein nanoparticles and ATP-triggered protein release in the cell. b Cellular uptake efficiency of ZIF-90/GFP. c Cellular uptake efficiency of ZIF-90/GFP in the presence of different endocytosis inhibitors. d CLSM images of HeLa cells treated with ZIF-90/GFP. LysoTracker Red was used for endosome/lysosome staining. Scale bar: 10 μm.
Enzymes are a class or proteins that can catalyze many complex reactions in organisms with high selectivity. So far, enzyme–MOF composites have been widely studied for catalysis, sensing, and detection [154,155,156,157]. Recently, cellular delivery of enzymes by MOF nanocarriers for cancer therapy has been reported by the Zhou group. These MOFs showed better selectivity and less systemic toxicity than conventional chemotherapy [158]. Tyrosinase was encapsulated into PCN-333(Al) (TYR@PCN-333) to form an enzyme–MOF nanoreactor to activate the cancer prodrug paracetamol (APAP). The reaction generated reactive oxygen species (ROS) and depleted glutathione (GSH), inducing cytotoxicity in drug-resistant cancer cells. Compared to free enzyme, the MOF nanocarrier provided protection against enzyme deactivation and thus extended the antitumor efficacy of TYR@PCN-333.
3.4 Challenges
Although remarkable achievements have been made to apply MOFs for drug delivery, several challenges still exist in this field. First, only limited studies on the kinetics of drug loading and release have been reported so far. Recently, the Horcajada group has demonstrated that the drug loading process is governed by the accessibility of cages in MOFs, while the loading capacity is influenced by the hydrophobicity/hydrophilicity of MOFs and the drug molecules [159]. For instance, the loading rates of hydrophilic acetylsalicylic acid (AAS) and hydrophobic isobutylphenylpropanoic acid (IBU) into UiO-66 are 0.0301 and 0.0295 M h–1, respectively. However, higher total drug loading capacity of IBU (35.5%) was observed compared to that of AAS (25.5%). It is worth noting that the solvent may also affect the drug loading rate. According to their studies, both the structure of MOFs and the hydrophobic/hydrophilic nature of the drug molecules could affect the rate of drug release. For example, a faster release of AAS from the open-structured MIL-100 (1 day) was observed, while a slower AAS release from the narrow 1D pore system of MIL-127 (6 days) was detected. Furthermore, a mismatch in hydrophobicity and hydrophilicity could result in a fast drug release. For example, hydrophilic AAS underwent a quick release from hydrophobic UiO-66 (1 day).
Another major challenge for clinical applications of MOF-based DDS is the potential toxicity. However, the existing literature is very limited and insufficient to draw a conclusion about the toxicity of MOF nanoparticles. So far, many in vitro toxicity studies have been conducted on different cell lines, making it very difficult to compare the obtained results. For instance, nanoZIF-8 (200 nm) was evaluated against three human cell lines, namely NCI-H292, HT-29, and HL-60. Results suggested that nanoZIF-8 is nontoxic to these cells [101]. However, in another report, nanoZIF-8 (90 nm) showed cytotoxicity toward HeLa and J774 cell lines [160]. Recently, the in vivo toxicity of nanoscale MOFs has been assessed against zebrafish embryos [161]. The study revealed that the toxicity of MOFs was mainly attributed to the leached metal ions. In contrary, three different Fe(III)-based MOF nanoparticles (MIL-88A, MIL-100, and MIL-88B_4CH3) were injected in rats at high doses. The results suggested that these MOF nanoparticles exhibited low acute toxicity and were rapidly sequestered by liver and spleen. According to the studies by Baati et al., the MOF nanoparticles could undergo further biodegradation and elimination in urine or feces without metabolization and causing significant toxicity [162]. In order to reach the clinical development stage of MOF nanoparticles, the performance of MOF-based DDS should be optimized for preclinical evaluation by conducting systematic in vivo studies on their stability, degradation mechanics, and side effects on normal organs.
4 Conclusions and Perspectives
During the past few decades, MOFs have been extensively studied for a variety of applications by their well-defined structure, high surface area, high porosity, tunable pore size, and easy functionalization. In particular, exploring MOFs as a nanocarrier for drug delivery in biomedical applications has attracted great interest in recent years. Currently, various molecules have been investigated as the therapeutic agents for disease treatment, such as anticancer drugs, nucleic acids, and proteins. In this review, we summarized four strategies commonly used to functionalize MOFs with therapeutic agents for drug delivery. They include surface adsorption, pore encapsulation, covalent binding, and functional molecules as the building block. The van der Waals interaction, π–π interaction, and hydrogen bonding are the main forces involved in surface adsorption and pore encapsulation approaches. Functional molecules are covalently bound to the framework through inorganic metal clusters or organic linkers by the covalent binding method. Moreover, functional molecules can be incorporated into the framework as organic ligands. Then, we thoroughly discussed recent progress of biological applications of MOF nanocarriers for drug delivery. Benefiting from unique advantages of MOFs, many drug molecules have been efficiently delivered by MOF nanoparticles. Among them, drugs, nucleic acids, and proteins were selected for discussion in this section.
Despite remarkable achievements made in this field, several challenges remain to be solved. First, although many functionalization methods have been reported, they all possess some limitations. For instance, molecules incorporated by surface adsorption and pore encapsulation tend to leak gradually owing to weak interaction forces. Covalent binding provides stronger interactions, but it requires complex synthetic procedures and may influence the activity of functional molecules. On the other hand, the organic ligands suitable for MOF synthesis are usually rigid and highly symmetrical, which makes it difficult to directly utilize biomolecules as the building block. Such limitations call for the development of advanced functionalization strategies to incorporate a wide variety of potential therapeutic agents into MOFs to explore their clinical applications. Second, the kinetics of drug loading and release, in vivo toxicity, degradation mechanism, and pharmacokinetics of MOF nanoparticles are still under study. Further investigations are required to rationally design MOF–drug conjugates with enhanced biostability, biocompatibility, and therapeutic efficacy. In conclusion, MOFs possess unique properties and show great promise for intracellular drug delivery to treat diseases. In the future, efforts should be focused on overcoming the noted challenges to fully realize the potential of MOFs as drug delivery systems in clinical applications.
References
S.T. Meek, J.A. Greathouse, M.D. Allendorf, Metal–organic frameworks: a rapidly growing class of versatile nanoporous materials. Adv. Mater. 23, 249–267 (2011). https://doi.org/10.1002/adma.201002854
H.-C. Zhou, J.R. Long, O.M. Yaghi, Introduction to Metal–organic frameworks. Chem. Rev. 112, 673–674 (2012). https://doi.org/10.1021/cr300014x
H. Furukawa, K.E. Cordova, M. O’Keeffe, O.M. Yaghi, The Chemistry and applications of metal–organic frameworks. Science 341, 1230444 (2013). https://doi.org/10.1126/science.1230444
O.M. Yaghi, G. Li, H. Li, Selective binding and removal of guests in a microporous metal–organic framework. Nature 378, 703–706 (1995). https://doi.org/10.1038/378703a0
H. Li, M. Eddaoudi, M. O'Keeffe, O.M. Yaghi, Design and synthesis of an exceptionally stable and highly porous metal–organic framework. Nature 402, 276–279 (1999). https://doi.org/10.1038/46248
J.-R. Li, R.J. Kuppler, H.-C. Zhou, Selective gas adsorption and separation in metal–organic frameworks. Chem. Soc. Rev. 38, 1477–1504 (2009). https://doi.org/10.1039/B802426J
Y.-S. Bae, R.Q. Snurr, Development and evaluation of porous materials for carbon dioxide separation and capture. Angew. Chem. Int. Ed. 50, 11586–11596 (2011). https://doi.org/10.1002/anie.201101891
K. Sumida, D.L. Rogow, J.A. Mason, T.M. McDonald, E.D. Bloch, Z.R. Herm, T.-H. Bae, J.R. Long, Carbon dioxide capture in metal–organic frameworks. Chem. Rev. 112, 724–781 (2012). https://doi.org/10.1021/cr2003272
M.P. Suh, H.J. Park, T.K. Prasad, D.-W. Lim, Hydrogen storage in metal–organic frameworks. Chem. Rev. 112, 782–835 (2012). https://doi.org/10.1021/cr200274s
B. Chen, S. **ang, G. Qian, Metal−organic frameworks with functional pores for recognition of small molecules. Acc. Chem. Res. 43, 1115–1124 (2010). https://doi.org/10.1021/ar100023y
N.A. Khan, S.H. Jhung, Adsorptive removal and separation of chemicals with metal-organic frameworks: contribution of π-complexation. J. Hazard. Mater. 325, 198–213 (2017). https://doi.org/10.1016/j.jhazmat.2016.11.070
J. Lee, O.K. Farha, J. Roberts, K.A. Scheidt, S.T. Nguyen, J.T. Hupp, Metal–organic framework materials as catalysts. Chem. Soc. Rev. 38, 1450–1459 (2009). https://doi.org/10.1039/B807080F
J. Liu, L. Chen, H. Cui, J. Zhang, L. Zhang, C.-Y. Su, Applications of metal–organic frameworks in heterogeneous supramolecular catalysis. Chem. Soc. Rev. 43, 6011–6061 (2014). https://doi.org/10.1039/C4CS00094C
Y.-B. Huang, J. Liang, X.-S. Wang, R. Cao, Multifunctional metal–organic framework catalysts: synergistic catalysis and tandem reactions. Chem. Soc. Rev. 46, 126–157 (2017). https://doi.org/10.1039/C6CS00250A
J.-D. **ao, H.-L. Jiang, Metal–organic frameworks for photocatalysis and photothermal catalysis. Acc. Chem. Res. 52, 356–366 (2019). https://doi.org/10.1021/acs.accounts.8b00521
Z. Hu, B.J. Deibert, J. Li, Luminescent metal–organic frameworks for chemical sensing and explosive detection. Chem. Soc. Rev. 43, 5815–5840 (2014). https://doi.org/10.1039/C4CS00010B
Y. Cui, B. Chen, G. Qian, Lanthanide metal–organic frameworks for luminescent sensing and light-emitting applications. Coord. Chem. Rev. 273–274, 76–86 (2014). https://doi.org/10.1016/j.ccr.2013.10.023
X. Zhang, W. Wang, Z. Hu, G. Wang, K. Uvdal, Coordination polymers for energy transfer: preparations, properties, sensing applications, and perspectives. Coord. Chem. Rev. 284, 206–235 (2015). https://doi.org/10.1016/j.ccr.2014.10.006
W.P. Lustig, S. Mukherjee, N.D. Rudd, A.V. Desai, J. Li, S.K. Ghosh, Metal–organic frameworks: functional luminescent and photonic materials for sensing applications. Chem. Soc. Rev. 46, 3242–3285 (2017). https://doi.org/10.1039/C6CS00930A
Y. Xu, Q. Li, H. Xue, H. Pang, Metal–organic frameworks for direct electrochemical applications. Coord. Chem. Rev. 376, 292–318 (2018). https://doi.org/10.1016/j.ccr.2018.08.010
S. Li, F. Huo, Metal–organic framework composites: from fundamentals to applications. Nanoscale 7, 7482–7501 (2015). https://doi.org/10.1039/C5NR00518C
Y. Zhang, L. Yang, L. Yan, G. Wang, A. Liu, Recent advances in the synthesis of spherical and nanoMOF-derived multifunctional porous carbon for nanomedicine applications. Coord. Chem. Rev. 391, 69–89 (2019). https://doi.org/10.1016/j.ccr.2019.04.006
R.C. Huxford, J.D. Rocca, W. Lin, Metal–organic frameworks as potential drug carriers. Curr. Opin. Chem. Biol. 14, 262–268 (2010). https://doi.org/10.1016/j.cbpa.2009.12.012
C.Y. Sun, C. Qin, X.L. Wang, Z.M. Su, Metal–organic frameworks as potential drug delivery systems. Expert Opin. Drug Deliv. 10, 89–101 (2013). https://doi.org/10.1517/17425247.2013.741583
M. Giménez-Marqués, T. Hidalgo, C. Serre, P. Horcajada, Nanostructured metal–organic frameworks and their bio-related applications. Coord. Chem. Rev. 307, 342–360 (2016). https://doi.org/10.1016/j.ccr.2015.08.008
B.A. Lakshmi, S. Kim, Current and emerging applications of nanostructured metal–organic frameworks in cancer-targeted theranostics. Mater. Sci. Eng. C 105, 110091 (2019). https://doi.org/10.1016/j.msec.2019.110091
L. Zhidong, F. Shuran, G. Chuying, L. Weicong, C. **xiang, L. Baohong, L. Jianqiang, Metal–organic framework (MOF)-based nanomaterials for biomedical applications. Curr. Med. Chem. 26, 3341–3369 (2019). https://doi.org/10.2174/0929867325666180214123500
J.K. Patra, G. Das, L.F. Fraceto, E.V.R. Campos, MdP Rodriguez-Torres et al., Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnol. 16, 71 (2018). https://doi.org/10.1186/s12951-018-0392-8
B. Yan, Lanthanide-functionalized metal–organic framework hybrid systems to create multiple luminescent centers for chemical sensing. Acc. Chem. Res. 50, 2789–2798 (2017). https://doi.org/10.1021/acs.accounts.7b00387
O.K. Farha, J.T. Hupp, Rational design, synthesis, purification, and activation of metal−organic framework materials. Acc. Chem. Res. 43, 1166–1175 (2010). https://doi.org/10.1021/ar1000617
K.K. Tanabe, S.M. Cohen, Postsynthetic modification of metal–organic frameworks—a progress report. Chem. Soc. Rev. 40, 498–519 (2011). https://doi.org/10.1039/C0CS00031K
W. Lu, Z. Wei, Z.-Y. Gu, T.-F. Liu, J. Park et al., Tuning the structure and function of metal–organic frameworks via linker design. Chem. Soc. Rev. 43, 5561–5593 (2014). https://doi.org/10.1039/C4CS00003J
R. Anand, F. Borghi, F. Manoli, I. Manet, V. Agostoni, P. Reschiglian, R. Gref, S. Monti, Host–guest interactions in Fe(III)-Trimesate MOF nanoparticles loaded with doxorubicin. J. Phys. Chem. B 118, 8532–8539 (2014). https://doi.org/10.1021/jp503809w
H. Ren, L. Zhang, J. An, T. Wang, L. Li et al., Polyacrylic acid@zeolitic imidazolate framework-8 nanoparticles with ultrahigh drug loading capability for pH-sensitive drug release. Chem. Commun. 50, 1000–1002 (2014). https://doi.org/10.1039/C3CC47666A
C. Adhikari, A. Chakraborty, Smart approach for in situ one-step encapsulation and controlled delivery of a chemotherapeutic drug using metal–organic framework-drug composites in aqueous media. ChemPhysChem 17, 1070–1077 (2016). https://doi.org/10.1002/cphc.201501012
X. Chen, M. Zhang, S. Li, L. Li, L. Zhang et al., Facile synthesis of polypyrrole@metal–organic framework core–shell nanocomposites for dual-mode imaging and synergistic chemo-photothermal therapy of cancer cells. J. Mater. Chem. B 5, 1772–1778 (2017). https://doi.org/10.1039/C6TB03218D
A. Bhattacharjee, S. Gumma, M.K. Purkait, Fe3O4 promoted metal organic framework MIL-100(Fe) for the controlled release of doxorubicin hydrochloride. Microporous Mesoporous Mater. 259, 203–210 (2018). https://doi.org/10.1016/j.micromeso.2017.10.020
W.J. Rieter, K.M. Pott, K.M.L. Taylor, W. Lin, Nanoscale coordination polymers for platinum-based anticancer drug delivery. J. Am. Chem. Soc. 130, 11584–11585 (2008). https://doi.org/10.1021/ja803383k
M.R. di Nunzio, V. Agostoni, B. Cohen, R. Gref, A. Douhal, A “ship in a bottle” strategy to load a hydrophilic anticancer drug in porous metal organic framework nanoparticles: efficient encapsulation, matrix stabilization, and photodelivery. J. Med. Chem. 57, 411–420 (2014). https://doi.org/10.1021/jm4017202
J. Zhuang, C.-H. Kuo, L.-Y. Chou, D.-Y. Liu, E. Weerapana, C.-K. Tsung, Optimized metal–organic-framework nanospheres for drug delivery: evaluation of small-molecule encapsulation. ACS Nano 8, 2812–2819 (2014). https://doi.org/10.1021/nn406590q
F.-M. Zhang, H. Dong, X. Zhang, X.-J. Sun, M. Liu, D.-D. Yang, X. Liu, J.-Z. Wei, Postsynthetic modification of ZIF-90 for potential targeted codelivery of two anticancer drugs. ACS Appl. Mater. Interfaces 9, 27332–27337 (2017). https://doi.org/10.1021/acsami.7b08451
W. Cai, H. Gao, C. Chu, X. Wang, J. Wang et al., Engineering phototheranostic nanoscale metal–organic frameworks for multimodal imaging-guided cancer therapy. ACS Appl. Mater. Interfaces 9, 2040–2051 (2017). https://doi.org/10.1021/acsami.6b11579
W. Wang, L. Wang, S. Liu, Z. **e, Metal–organic frameworks@polymer composites containing cyanines for near-infrared fluorescence imaging and photothermal tumor therapy. Bioconjugate Chem. 28, 2784–2793 (2017). https://doi.org/10.1021/acs.bioconjchem.7b00508
K. Lu, C. He, W. Lin, Nanoscale metal–organic framework for highly effective photodynamic therapy of resistant head and neck cancer. J. Am. Chem. Soc. 136, 16712–16715 (2014). https://doi.org/10.1021/ja508679h
M. Lismont, L. Dreesen, S. Wuttke, Metal–organic framework nanoparticles in photodynamic therapy: current status and perspectives. Adv. Funct. Mater. 27, 1606314 (2017). https://doi.org/10.1002/adfm.201606314
J. Zhuang, A.P. Young, C.-K. Tsung, Integration of biomolecules with metal–organic frameworks. Small 13, 1700880 (2017). https://doi.org/10.1002/smll.201700880
J. Mehta, N. Bhardwaj, S.K. Bhardwaj, K.-H. Kim, A. Deep, Recent advances in enzyme immobilization techniques: metal–organic frameworks as novel substrates. Coord. Chem. Rev. 322, 30–40 (2016). https://doi.org/10.1016/j.ccr.2016.05.007
T.J. Pisklak, M. Macías, D.H. Coutinho, R.S. Huang, K.J. Balkus, Hybrid materials for immobilization of MP-11 catalyst. Top. Catal. 38, 269–278 (2006). https://doi.org/10.1007/s11244-006-0025-6
W.-L. Liu, S.-H. Lo, B. Singco, C.-C. Yang, H.-Y. Huang, C.-H. Lin, Novel trypsin–FITC@MOF bioreactor efficiently catalyzes protein digestion. J. Mater. Chem. B 1, 928–932 (2013). https://doi.org/10.1039/C3TB00257H
W.-L. Liu, C.-Y. Wu, C.-Y. Chen, B. Singco, C.-H. Lin, H.-Y. Huang, Fast multipoint immobilized MOF bioreactor. Chem. Eur. J. 20, 8923–8928 (2014). https://doi.org/10.1002/chem.201400270
W. Ma, Q. Jiang, P. Yu, L. Yang, L. Mao, Zeolitic imidazolate framework-based electrochemical biosensor for in vivo electrochemical measurements. Anal. Chem. 85, 7550–7557 (2013). https://doi.org/10.1021/ac401576u
G.-H. Qiu, Z.-H. Weng, P.-P. Hu, W.-J. Duan, B.-P. **e, B. Sun, X.-Y. Tang, J.-X. Chen, Synchronous detection of ebolavirus conserved RNA sequences and ebolavirus-encoded miRNA-like fragment based on a zwitterionic copper (II) metal–organic framework. Talanta 180, 396–402 (2018). https://doi.org/10.1016/j.talanta.2017.12.045
S. Peng, B. Bie, Y. Sun, M. Liu, H. Cong et al., Metal–organic frameworks for precise inclusion of single-stranded DNA and transfection in immune cells. Nat. Commun. 9, 1293 (2018). https://doi.org/10.1038/s41467-018-03650-w
T. Simon-Yarza, A. Mielcarek, P. Couvreur, C. Serre, Nanoparticles of metal–organic frameworks: on the road to in vivo efficacy in biomedicine. Adv. Mater. 30, 1707365 (2018). https://doi.org/10.1002/adma.201707365
X. Chen, R. Tong, Z. Shi, B. Yang, H. Liu et al., MOF nanoparticles with encapsulated autophagy inhibitor in controlled drug delivery system for antitumor. ACS Appl. Mater. Interfaces 10, 2328–2337 (2018). https://doi.org/10.1021/acsami.7b16522
X. Wu, J. Ge, C. Yang, M. Hou, Z. Liu, Facile synthesis of multiple enzyme-containing metal–organic frameworks in a biomolecule-friendly environment. Chem. Commun. 51, 13408–13411 (2015). https://doi.org/10.1039/C5CC05136C
C. Hou, Y. Wang, Q. Ding, L. Jiang, M. Li et al., Facile synthesis of enzyme-embedded magnetic metal–organic frameworks as a reusable mimic multi-enzyme system: mimetic peroxidase properties and colorimetric sensor. Nanoscale 7, 18770–18779 (2015). https://doi.org/10.1039/C5NR04994F
V. Lykourinou, Y. Chen, X.-S. Wang, L. Meng, T. Hoang, L.-J. Ming, R.L. Musselman, S. Ma, Immobilization of MP-11 into a mesoporous metal–organic framework, MP-11@mesoMOF: a new platform for enzymatic catalysis. J. Am. Chem. Soc. 133, 10382–10385 (2011). https://doi.org/10.1021/ja2038003
Y. Chen, V. Lykourinou, C. Vetromile, T. Hoang, L.-J. Ming, R.W. Larsen, S. Ma, How can proteins enter the interior of a MOF? investigation of cytochrome c translocation into a MOF consisting of mesoporous cages with microporous windows. J. Am. Chem. Soc. 134, 13188–13191 (2012). https://doi.org/10.1021/ja305144x
D. Feng, T.-F. Liu, J. Su, M. Bosch, Z. Wei et al., Stable metal–organic frameworks containing single-molecule traps for enzyme encapsulation. Nat. Commun. 6, 5979 (2015). https://doi.org/10.1038/ncomms6979
Z. Wang, S.M. Cohen, Postsynthetic modification of metal–organic frameworks. Chem. Soc. Rev. 38, 1315–1329 (2009). https://doi.org/10.1039/B802258P
S. Jung, Y. Kim, S.-J. Kim, T.-H. Kwon, S. Huh, S. Park, Bio-functionalization of metal–organic frameworks by covalent protein conjugation. Chem. Commun. 47, 2904–2906 (2011). https://doi.org/10.1039/C0CC03288C
Y.-H. Shih, S.-H. Lo, N.-S. Yang, B. Singco, Y.-J. Cheng et al., Trypsin-immobilized metal–organic framework as a biocatalyst in proteomics analysis. ChemPlusChem 77, 982–986 (2012). https://doi.org/10.1002/cplu.201200186
C. Tudisco, G. Zolubas, B. Seoane, H.R. Zafarani, M. Kazemzad, J. Gascon, P.L. Hagedoorn, L. Rassaei, Covalent immobilization of glucose oxidase on amino MOFs via post-synthetic modification. RSC Adv. 6, 108051–108055 (2016). https://doi.org/10.1039/C6RA19976C
S.-L. Cao, D.-M. Yue, X.-H. Li, T.J. Smith, N. Li et al., Novel nano-/micro-biocatalyst: soybean epoxide hydrolase immobilized on UiO-66-NH2 MOF for efficient biosynthesis of enantiopure (R)-1, 2-octanediol in deep eutectic solvents. ACS Sustainable Chem. Eng. 4, 3586–3595 (2016). https://doi.org/10.1021/acssuschemeng.6b00777
A.H. El-Sagheer, T. Brown, Click chemistry with DNA. Chem. Soc. Rev. 39, 1388–1405 (2010). https://doi.org/10.1039/B901971P
P.-Z. Li, X.-J. Wang, Y. Zhao, Click chemistry as a versatile reaction for construction and modification of metal–organic frameworks. Coord. Chem. Rev. 380, 484–518 (2019). https://doi.org/10.1016/j.ccr.2018.11.006
W. Morris, W.E. Briley, E. Auyeung, M.D. Cabezas, C.A. Mirkin, Nucleic acid-metal organic framework (MOF) nanoparticle conjugates. J. Am. Chem. Soc. 136, 7261–7264 (2014). https://doi.org/10.1021/ja503215w
S. Wang, C.M. McGuirk, M.B. Ross, S. Wang, P. Chen, H. **ng, Y. Liu, C.A. Mirkin, General and direct method for preparing oligonucleotide-functionalized metal–organic framework nanoparticles. J. Am. Chem. Soc. 139, 9827–9830 (2017). https://doi.org/10.1021/jacs.7b05633
Y. Sun, L. Sun, D. Feng, H.-C. Zhou, An in situ one-pot synthetic approach towards multivariate zirconium MOFs. Angew. Chem. Int. Ed. 55, 6471–6475 (2016). https://doi.org/10.1002/anie.201602274
C.D.L. Saunders, N. Burford, U. Werner-Zwanziger, R. McDonald, Preparation and comprehensive characterization of [Hg6(Alanine)4(NO3)4]·H2O. Inorg. Chem. 47, 3693–3699 (2008). https://doi.org/10.1021/ic702321d
J. Rabone, Y.-F. Yue, S.Y. Chong, K.C. Stylianou, J. Bacsa et al., An adaptable peptide-based porous material. Science 329, 1053–1057 (2010). https://doi.org/10.1126/science.1190672
A.P. Katsoulidis, K.S. Park, D. Antypov, C. Martí-Gastaldo, G.J. Miller et al., Guest-adaptable and water-stable peptide-based porous materials by imidazolate side chain control. Angew. Chem. Int. Ed. 53, 193–198 (2014). https://doi.org/10.1002/anie.201307074
S.L. Anderson, K.C. Stylianou, Biologically derived metal organic frameworks. Coord. Chem. Rev. 349, 102–128 (2017). https://doi.org/10.1016/j.ccr.2017.07.012
S. Rojas, T. Devic, P. Horcajada, Metal organic frameworks based on bioactive components. J. Mater. Chem. B 5, 2560–2573 (2017). https://doi.org/10.1039/C6TB03217F
S. Verma, A.K. Mishra, J. Kumar, The many facets of adenine: coordination, crystal patterns, and catalysis. Acc. Chem. Res. 43, 79–91 (2010). https://doi.org/10.1021/ar9001334
J. An, S.J. Geib, N.L. Rosi, Cation-triggered drug release from a porous zinc−adeninate metal−organic framework. J. Am. Chem. Soc. 131, 8376–8377 (2009). https://doi.org/10.1021/ja902972w
J. An, O.K. Farha, J.T. Hupp, E. Pohl, J.I. Yeh, N.L. Rosi, Metal–adeninate vertices for the construction of an exceptionally porous metal–organic framework. Nat. Commun. 3, 604 (2012). https://doi.org/10.1038/ncomms1618
M. Zhang, W. Lu, J.-R. Li, M. Bosch, Y.-P. Chen et al., Design and synthesis of nucleobase-incorporated metal–organic materials. Inorg. Chem. Front. 1, 159–162 (2014). https://doi.org/10.1039/C3QI00042G
L. Galluzzi, A. Buqué, O. Kepp, L. Zitvogel, G. Kroemer, Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28, 690–714 (2015). https://doi.org/10.1016/j.ccell.2015.10.012
D. Mao, F. Hu, Kenry, S. Ji, W. Wu, D. Ding, D. Kong, B. Liu, Metal–organic-framework-assisted in vivo bacterial metabolic labeling and precise antibacterial therapy. Adv. Mater. 30, 1706831 (2018). https://doi.org/10.1002/adma.201706831
Y. Chen, P. Li, J.A. Modica, R.J. Drout, O.K. Farha, Acid-resistant mesoporous metal–organic framework toward oral insulin delivery: protein encapsulation, protection, and release. J. Am. Chem. Soc. 140, 5678–5681 (2018). https://doi.org/10.1021/jacs.8b02089
D.F. Sava Gallis, K.S. Butler, J.O. Agola, C.J. Pearce, A.A. McBride, Antibacterial countermeasures via metal–organic framework-supported sustained therapeutic release. ACS Appl. Mater. Interfaces 11, 7782–7791 (2019). https://doi.org/10.1021/acsami.8b21698
J. Gandara-Loe, I. Ortuño-Lizarán, L. Fernández-Sanchez, J.L. Alió, N. Cuenca, A. Vega-Estrada, J. Silvestre-Albero, Metal–organic frameworks as drug delivery platforms for ocular therapeutics. ACS Appl. Mater. Interfaces 11, 1924–1931 (2019). https://doi.org/10.1021/acsami.8b20222
I. Mellman, Endocytosis and molecular sorting. Annu. Rev. Cell Dev. Biol. 12, 575–625 (1996). https://doi.org/10.1146/annurev.cellbio.12.1.575
J. Rejman, V. Oberle, I.S. Zuhorn, D. Hoekstra, Size-dependent internalization of particles via the pathways of clathrin—and caveolae-mediated endocytosis. Biochem. J. 377, 159–169 (2004). https://doi.org/10.1042/bj20031253
S. Sevimli, S. Sagnella, A. Macmillan, R. Whan, M. Kavallaris, V. Bulmus, T.P. Davis, The endocytic pathway and therapeutic efficiency of doxorubicin conjugated cholesterol-derived polymers. Biomater. Sci. 3, 323–335 (2015). https://doi.org/10.1039/C4BM00224E
H.T. McMahon, E. Boucrot, Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell Biol. 12, 517–533 (2011). https://doi.org/10.1038/nrm3151
L. Pelkmans, T. Bürli, M. Zerial, A. Helenius, Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic. Cell 118, 767–780 (2004). https://doi.org/10.1016/j.cell.2004.09.003
S. Mayor, R.E. Pagano, Pathways of clathrin-independent endocytosis. Nat. Rev. Mol. Cell Biol. 8, 603–612 (2007). https://doi.org/10.1038/nrm2216
Y. Fu, Q. Feng, Y. Chen, Y. Shen, Q. Su, Y. Zhang, X. Zhou, Y. Cheng, Comparison of two approaches for the attachment of a drug to gold nanoparticles and their anticancer activities. Mol. Pharm. 13, 3308–3317 (2016). https://doi.org/10.1021/acs.molpharmaceut.6b00619
G. Vassal, A. Gouyette, O. Hartmann, J.L. Pico, J. Lemerle, Pharmacokinetics of high-dose busulfan in children. Cancer Chemother. Pharmacol. 24, 386–390 (1989). https://doi.org/10.1007/bf00257448
J. Sehouli, G. Oskay-Özcelik, Current role and future aspects of topotecan in relapsed ovarian cancer. Curr. Med. Res. Opin. 25, 639–651 (2009). https://doi.org/10.1185/03007990802707139
S.J. Nicum, M.E.R. O’Brien, Topotecan for the treatment of small-cell lung cancer. Expert Rev. Anticancer Ther. 7, 795–801 (2007). https://doi.org/10.1586/14737140.7.6.795
M.-X. Wu, Y.-W. Yang, Metal–organic framework (MOF)-based drug/cargo delivery and cancer therapy. Adv. Mater. 29, 1606134 (2017). https://doi.org/10.1002/adma.201606134
S.R. Venna, J.B. Jasinski, M.A. Carreon, Structural evolution of zeolitic imidazolate framework-8. J. Am. Chem. Soc. 132, 18030–18033 (2010). https://doi.org/10.1021/ja109268m
Q. Yang, S. Ren, Q. Zhao, R. Lu, C. Hang, Z. Chen, H. Zheng, Selective separation of methyl orange from water using magnetic ZIF-67 composites. Chem. Eng. J. 333, 49–57 (2018). https://doi.org/10.1016/j.cej.2017.09.099
Z. Wang, X. Tang, X. Wang, D. Yang, C. Yang, Y. Lou, J. Chen, N. He, Near-infrared light-induced dissociation of zeolitic imidazole framework-8 (ZIF-8) with encapsulated CuS nanoparticles and their application as a therapeutic nanoplatform. Chem. Commun. 52, 12210–12213 (2016). https://doi.org/10.1039/C6CC06616J
B. Chen, Z. Yang, Y. Zhu, Y. **a, Zeolitic imidazolate framework materials: recent progress in synthesis and applications. J. Mater. Chem. A 2, 16811–16831 (2014). https://doi.org/10.1039/C4TA02984D
K.S. Park, Z. Ni, A.P. Côté, J.Y. Choi, R. Huang et al., Exceptional chemical and thermal stability of zeolitic imidazolate frameworks. Proc. Natl. Acad. Sci. USA 103, 10186–10191 (2006). https://doi.org/10.1073/pnas.0602439103
I.B. Vasconcelos, T.G. da Silva, G.C.G. Militão, T.A. Soares, N.M. Rodrigues et al., Cytotoxicity and slow release of the anti-cancer drug doxorubicin from ZIF-8. RSC Adv. 2, 9437–9442 (2012). https://doi.org/10.1039/C2RA21087H
C.-Y. Sun, C. Qin, X.-L. Wang, G.-S. Yang, K.-Z. Shao et al., Zeolitic imidazolate framework-8 as efficient pH-sensitive drug delivery vehicle. Dalton Trans. 41, 6906–6909 (2012). https://doi.org/10.1039/C2DT30357D
H. Zheng, Y. Zhang, L. Liu, W. Wan, P. Guo, A.M. Nyström, X. Zou, One-pot synthesis of metal–organic frameworks with encapsulated target molecules and their applications for controlled drug delivery. J. Am. Chem. Soc. 138, 962–968 (2016). https://doi.org/10.1021/jacs.5b11720
F. Wang, D. Zhang, Q. Zhang, Y. Chen, D. Zheng et al., Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance. Biomaterials 32, 9444–9456 (2011). https://doi.org/10.1016/j.biomaterials.2011.08.041
H.M. Abdallah, A.M. Al-Abd, R.S. El-Dine, A.M. El-Halawany, P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review. J. Adv. Res. 6, 45–62 (2015). https://doi.org/10.1016/j.jare.2014.11.008
H. Zhang, W. Jiang, R. Liu, J. Zhang, D. Zhang, Z. Li, Y. Luan, Rational design of metal organic framework nanocarrier-based codelivery system of doxorubicin hydrochloride/verapamil hydrochloride for overcoming multidrug resistance with efficient targeted cancer therapy. ACS Appl. Mater. Interfaces 9, 19687–19697 (2017). https://doi.org/10.1021/acsami.7b05142
Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387–6392 (1986). https://doi.org/10.1016/0304-3835(86)90075-3
H. Maeda, Y. Matsumura, Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther, Drug 6, 193–210 (1989). https://europepmc.org/article/med/2692843
X. Qi, Z. Chang, D. Zhang, K.J. Binder, S. Shen et al., Harnessing surface-functionalized metal–organic frameworks for selective tumor cell capture. Chem. Mater. 29, 8052–8056 (2017). https://doi.org/10.1021/acs.chemmater.7b03269
P. Horcajada, C. Serre, M. Vallet-Regí, M. Sebban, F. Taulelle, G. Férey, Metal–organic frameworks as efficient materials for drug delivery. Angew. Chem. Int. Ed. 45, 5974–5978 (2006). https://doi.org/10.1002/anie.200601878
P. Horcajada, T. Chalati, C. Serre, B. Gillet, C. Sebrie et al., Porous metal–organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat. Mater. 9, 172–178 (2010). https://doi.org/10.1038/nmat2608
K.M.L. Taylor-Pashow, J. Della Rocca, Z. **e, S. Tran, W. Lin, Postsynthetic modifications of iron-carboxylate nanoscale metal−organic frameworks for imaging and drug delivery. J. Am. Chem. Soc. 131, 14261–14263 (2009). https://doi.org/10.1021/ja906198y
X.-G. Wang, Z.-Y. Dong, H. Cheng, S.-S. Wan, W.-H. Chen et al., A multifunctional metal–organic framework based tumor targeting drug delivery system for cancer therapy. Nanoscale 7, 16061–16070 (2015). https://doi.org/10.1039/C5NR04045K
B. Illes, P. Hirschle, S. Barnert, V. Cauda, S. Wuttke, H. Engelke, Exosome-coated metal–organic framework nanoparticles: an efficient drug delivery platform. Chem. Mater. 29, 8042–8046 (2017). https://doi.org/10.1021/acs.chemmater.7b02358
S. Senapati, A.K. Mahanta, S. Kumar, P. Maiti, Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct. Target. Ther. 3, 7 (2018). https://doi.org/10.1038/s41392-017-0004-3
S. Sharma, K. Sethi, I. Roy, Magnetic nanoscale metal–organic frameworks for magnetically aided drug delivery and photodynamic therapy. New J. Chem. 41, 11860–11866 (2017). https://doi.org/10.1039/C7NJ02032E
J. Chen, J. Liu, Y. Hu, Z. Tian, Y. Zhu, Metal–organic framework-coated magnetite nanoparticles for synergistic magnetic hyperthermia and chemotherapy with pH-triggered drug release. Sci. Technol. Adv. Mater. 20, 1043–1054 (2019). https://doi.org/10.1080/14686996.2019.1682467
X. Du, R. Fan, L. Qiang, K. **ng, H. Ye et al., Controlled Zn2+-triggered drug release by preferred coordination of open active sites within functionalization indium metal organic frameworks. ACS Appl. Mater. Interfaces 9, 28939–28948 (2017). https://doi.org/10.1021/acsami.7b09227
X. Meng, J. Deng, F. Liu, T. Guo, M. Liu et al., Triggered all-active metal organic framework: ferroptosis machinery contributes to the apoptotic photodynamic antitumor therapy. Nano Lett. 19, 7866–7876 (2019). https://doi.org/10.1021/acs.nanolett.9b02904
M.H. Teplensky, M. Fantham, P. Li, T.C. Wang, J.P. Mehta et al., Temperature treatment of highly porous zirconium-containing metal–organic frameworks extends drug delivery release. J. Am. Chem. Soc. 139, 7522–7532 (2017). https://doi.org/10.1021/jacs.7b01451
W. Lin, Y. Cui, Y. Yang, Q. Hu, G. Qian, A biocompatible metal–organic framework as a pH and temperature dual-responsive drug carrier. Dalton Trans. 47, 15882–15887 (2018). https://doi.org/10.1039/C8DT03202E
K. Jiang, L. Zhang, Q. Hu, D. Zhao, T. **a et al., Pressure controlled drug release in a Zr-cluster-based MOF. J. Mater. Chem. B 4, 6398–6401 (2016). https://doi.org/10.1039/C6TB01756H
E. Lashkari, H. Wang, L. Liu, J. Li, K. Yam, Innovative application of metal-organic frameworks for encapsulation and controlled release of allyl isothiocyanate. Food Chem. 221, 926–935 (2017). https://doi.org/10.1016/j.foodchem.2016.11.072
B. Lei, M. Wang, Z. Jiang, W. Qi, R. Su, Z. He, Constructing redox-responsive metal–organic framework nanocarriers for anticancer drug delivery. ACS Appl. Mater. Interfaces 10, 16698–16706 (2018). https://doi.org/10.1021/acsami.7b19693
Y. Duan, F. Ye, Y. Huang, Y. Qin, C. He, S. Zhao, One-pot synthesis of a metal–organic framework-based drug carrier for intelligent glucose-responsive insulin delivery. Chem. Commun. 54, 5377–5380 (2018). https://doi.org/10.1039/C8CC02708K
Z. Luo, L. Jiang, S. Yang, Z. Li, W.M.W. Soh, L. Zheng, X.J. Loh, Y.-L. Wu, Light-induced redox-responsive smart drug delivery system by using selenium-containing polymer@MOF shell/core nanocomposite. Adv. Healthcare Mater. 8, 1900406 (2019). https://doi.org/10.1002/adhm.201900406
Y. Li, K. Zhang, P. Liu, M. Chen, Y. Zhong et al., Encapsulation of plasmid DNA by nanoscale metal–organic frameworks for efficient gene transportation and expression. Adv. Mater. 31, 1901570 (2019). https://doi.org/10.1002/adma.201901570
A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, C.C. Mello, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806–811 (1998). https://doi.org/10.1038/35888
C. He, K. Lu, D. Liu, W. Lin, Nanoscale metal–organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells. J. Am. Chem. Soc. 136, 5181–5184 (2014). https://doi.org/10.1021/ja4098862
Q. Chen, M. Xu, W. Zheng, T. Xu, H. Deng, J. Liu, Se/Ru-decorated porous metal–organic framework nanoparticles for the delivery of pooled siRNAs to reversing multidrug resistance in taxol-resistant breast cancer cells. ACS Appl. Mater. Interfaces 9, 6712–6724 (2017). https://doi.org/10.1021/acsami.6b12792
R. Stoltenburg, C. Reinemann, B. Strehlitz, SELEX—A (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng. 24, 381–403 (2007). https://doi.org/10.1016/j.bioeng.2007.06.001
K.-M. Song, S. Lee, C. Ban, Aptamers and their biological applications. Sensors 12, 612–631 (2012). https://doi.org/10.3390/s120100612
P. Röthlisberger, M. Hollenstein, Aptamer chemistry. Adv. Drug Delivery Rev. 134, 3–21 (2018). https://doi.org/10.1016/j.addr.2018.04.007
A.D. Keefe, S. Pai, A. Ellington, Aptamers as therapeutics. Nat. Rev. Drug Discovery 9, 537–550 (2010). https://doi.org/10.1038/nrd3141
P. Sundaram, H. Kurniawan, M.E. Byrne, J. Wower, Therapeutic RNA aptamers in clinical trials. Eur. J. Pharm. Sci. 48, 259–271 (2013). https://doi.org/10.1016/j.ejps.2012.10.014
H.-M. Meng, H. Liu, H. Kuai, R. Peng, L. Mo, X.-B. Zhang, Aptamer-integrated DNA nanostructures for biosensing, bioimaging and cancer therapy. Chem. Soc. Rev. 45, 2583–2602 (2016). https://doi.org/10.1039/C5CS00645G
M. Liu, X. Yu, Z. Chen, T. Yang, D. Yang et al., Aptamer selection and applications for breast cancer diagnostics and therapy. J. Nanobiotechnology 15, 81 (2017). https://doi.org/10.1186/s12951-017-0311-4
D. Shangguan, Y. Li, Z. Tang, Z.C. Cao, H.W. Chen et al., Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. USA 103, 11838–11843 (2006). https://doi.org/10.1073/pnas.0602615103
X. Fang, W. Tan, Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc. Chem. Res. 43, 48–57 (2010). https://doi.org/10.1021/ar900101s
K. Sefah, D. Shangguan, X. **ong, M.B. O'Donoghue, W. Tan, Development of DNA aptamers using cell-SELEX. Nat. Protoc. 5, 1169–1185 (2010). https://doi.org/10.1038/nprot.2010.66
W. Tan, M.J. Donovan, J. Jiang, Aptamers from cell-based selection for bioanalytical applications. Chem. Rev. 113, 2842–2862 (2013). https://doi.org/10.1021/cr300468w
G. Wang, J. Liu, K. Chen, Y. Xu, B. Liu et al., Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX. Sci. Rep. 7, 7179 (2017). https://doi.org/10.1038/s41598-017-05840-w
K. Sefah, Z.W. Tang, D.H. Shangguan, H. Chen, D. Lopez-Colon et al., Molecular recognition of acute myeloid leukemia using aptamers. Leukemia 23, 235–244 (2009). https://doi.org/10.1038/leu.2008.335
H.W. Chen, C.D. Medley, K. Sefah, D. Shangguan, Z. Tang, L. Meng, J.E. Smith, W. Tan, Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem 3, 991–1001 (2008). https://doi.org/10.1002/cmdc.200800030
P. Parekh, Z. Tang, P.C. Turner, R.W. Moyer, W. Tan, Aptamers recognizing glycosylated hemagglutinin expressed on the surface of vaccinia virus-infected cells. Anal. Chem. 82, 8642–8649 (2010). https://doi.org/10.1021/ac101801j
I.T. Teng, X. Li, H.A. Yadikar, Z. Yang, L. Li et al., Identification and characterization of DNA aptamers specific for phosphorylation epitopes of Tau protein. J. Am. Chem. Soc. 140, 14314–14323 (2018). https://doi.org/10.1021/jacs.8b08645
F. Su, Q. Jia, Z. Li, M. Wang, L. He et al., Aptamer-templated silver nanoclusters embedded in zirconium metal–organic framework for targeted antitumor drug delivery. Microporous Mesoporous Mater. 275, 152–162 (2019). https://doi.org/10.1016/j.micromeso.2018.08.026
W.-H. Chen, X. Yu, W.-C. Liao, Y.S. Sohn, A. Cecconello, A. Kozell, R. Nechushtai, I. Willner, ATP-responsive aptamer-based metal–organic framework nanoparticles (NMOFs) for the controlled release of loads and drugs. Adv. Funct. Mater. 27, 1702102 (2017). https://doi.org/10.1002/adfm.201702102
W.-H. Chen, G.-F. Luo, M. Vázquez-González, R. Cazelles, Y.S. Sohn, R. Nechushtai, Y. Mandel, I. Willner, Glucose-responsive metal–organic-framework nanoparticles act as “smart” sense-and-treat carriers. ACS Nano 12, 7538–7545 (2018). https://doi.org/10.1021/acsnano.8b03417
Z. Wang, Y. Fu, Z. Kang, X. Liu, N. Chen et al., Organelle-specific triggered release of immunostimulatory oligonucleotides from intrinsically coordinated DNA–metal–organic frameworks with soluble exoskeleton. J. Am. Chem. Soc. 139, 15784–15791 (2017). https://doi.org/10.1021/jacs.7b07895
S. Wang, Y. Chen, S. Wang, P. Li, C.A. Mirkin, O.K. Farha, DNA-functionalized metal–organic framework nanoparticles for intracellular delivery of proteins. J. Am. Chem. Soc. 141, 2215–2219 (2019). https://doi.org/10.1021/jacs.8b12705
Z. Liang, Z. Yang, H. Yuan, C. Wang, J. Qi, K. Liu, R. Cao, H. Zheng, A protein@metal–organic framework nanocomposite for pH-triggered anticancer drug delivery. Dalton Trans. 47, 10223–10228 (2018). https://doi.org/10.1039/C8DT01789A
X. Yang, Q. Tang, Y. Jiang, M. Zhang, M. Wang, L. Mao, Nanoscale ATP-responsive zeolitic imidazole framework-90 as a general platform for cytosolic protein delivery and genome editing. J. Am. Chem. Soc. 141, 3782–3786 (2019). https://doi.org/10.1021/jacs.8b11996
E. Gkaniatsou, C. Sicard, R. Ricoux, J.-P. Mahy, N. Steunou, C. Serre, Metal–organic frameworks: a novel host platform for enzymatic catalysis and detection. Mater. Horiz. 4, 55–63 (2017). https://doi.org/10.1039/C6MH00312E
S. Kempahanumakkagari, V. Kumar, P. Samaddar, P. Kumar, T. Ramakrishnappa, K.-H. Kim, Biomolecule-embedded metal-organic frameworks as an innovative sensing platform. Biotechnol. Adv. 36, 467–481 (2018). https://doi.org/10.1016/j.biotechadv.2018.01.014
Q. Qiu, H. Chen, Y. Wang, Y. Ying, Recent advances in the rational synthesis and sensing applications of metal-organic framework biocomposites. Coord. Chem. Rev. 387, 60–78 (2019). https://doi.org/10.1016/j.ccr.2019.02.009
H. An, M. Li, J. Gao, Z. Zhang, S. Ma, Y. Chen, Incorporation of biomolecules in metal-organic frameworks for advanced applications. Coord. Chem. Rev. 384, 90–106 (2019). https://doi.org/10.1016/j.ccr.2019.01.001
X. Lian, Y. Huang, Y. Zhu, Y. Fang, R. Zhao et al., Enzyme-MOF nanoreactor activates nontoxic paracetamol for cancer therapy. Angew. Chem. Int. Ed. 57, 5725–5730 (2018). https://doi.org/10.1002/anie.201801378
S. Rojas, I. Colinet, D. Cunha, T. Hidalgo, F. Salles, C. Serre, N. Guillou, P. Horcajada, Toward understanding drug incorporation and delivery from biocompatible metal–organic frameworks in view of cutaneous administration. ACS Omega 3, 2994–3003 (2018). https://doi.org/10.1021/acsomega.8b00185
C. Tamames-Tabar, D. Cunha, E. Imbuluzqueta, F. Ragon, C. Serre, M.J. Blanco-Prieto, P. Horcajada, Cytotoxicity of nanoscaled metal–organic frameworks. J. Mater. Chem. B 2, 262–271 (2014). https://doi.org/10.1039/C3TB20832J
À. Ruyra, A. Yazdi, J. Espín, A. Carné-Sánchez, N. Roher, J. Lorenzo, I. Imaz, D. Maspoch, Synthesis, culture medium stability, and in vitro and in vivo zebrafish embryo toxicity of metal–organic framework nanoparticles. Chem. Eur. J. 21, 2508–2518 (2015). https://doi.org/10.1002/chem.201405380
T. Baati, L. Njim, F. Neffati, A. Kerkeni, M. Bouttemi et al., In depth analysis of the in vivo toxicity of nanoparticles of porous iron(iii) metal–organic frameworks. Chem. Sci. 4, 1597–1607 (2013). https://doi.org/10.1039/C3SC22116D
N. Stock, S. Biswas, Synthesis of metal-organic frameworks (MOFs): routes to various MOF topologies, morphologies, and composites. Chem. Rev. 112, 933–969 (2012). https://doi.org/10.1021/cr200304e
E. Abbasi, S.F. Aval, A. Akbarzadeh, M. Milani, H.T. Nasrabadi et al., Dendrimers: synthesis, applications, and properties. Nanoscale Res. Lett. 9, 247 (2014). https://doi.org/10.1186/1556-276X-9-247
Z. Li, J.C. Barnes, A. Bosoy, J.F. Stoddart, J.I. Zink, Mesoporous silica nanoparticles in biomedical applications. Chem. Soc. Rev. 41, 2590–2605 (2012). https://doi.org/10.1039/C1CS15246G
S. Wang, C.M. McGuirk, A. d'Aquino, J.A. Mason, C.A. Mirkin, Metal–organic framework nanoparticles. Adv. Mater. 30, 1800202 (2018). https://doi.org/10.1002/adma.201800202
P. Hirschle, T. Preiß, F. Auras, A. Pick, J. Völkner et al., Exploration of MOF nanoparticle sizes using various physical characterization methods—is what you measure what you get? CrystEngComm 18, 4359–4368 (2016). https://doi.org/10.1039/C6CE00198J
S. Svenson, Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm. 71, 445–462 (2009). https://doi.org/10.1016/j.ejpb.2008.09.023
Y.-S. Lin, K.R. Hurley, C.L. Haynes, Critical considerations in the biomedical use of mesoporous silica nanoparticles. J. Phys. Chem. Lett. 3, 364–374 (2012). https://doi.org/10.1021/jz2013837
M. Vallet-Regí, F. Balas, D. Arcos, Mesoporous materials for drug delivery. Angew. Chem. Int. Ed. 46, 7548–7558 (2007). https://doi.org/10.1002/anie.200604488
J. Zhu, X. Shi, Dendrimer-based nanodevices for targeted drug delivery applications. J. Mater. Chem. B 1, 4199–4211 (2013). https://doi.org/10.1039/C3TB20724B
E.M. Flanigen, J.M. Bennett, R.W. Grose, J.P. Cohen, R.L. Patton, R.M. Kirchner, J.V. Smith, Silicalite, a new hydrophobic crystalline silica molecular sieve. Nature 271, 512–516 (1978). https://doi.org/10.1038/271512a0
O.M. Yaghi, M. O'Keeffe, N.W. Ockwig, H.K. Chae, M. Eddaoudi, J. Kim, Reticular synthesis and the design of new materials. Nature 423, 705–714 (2003). https://doi.org/10.1038/nature01650
O.A. Matthews, A.N. Shipway, J.F. Stoddart, Dendrimers—Branching out from curiosities into new technologies. Prog. Polym. Sci. 23, 1–56 (1998). https://doi.org/10.1016/S0079-6700(97)00025-7
C. Argyo, V. Weiss, C. Bräuchle, T. Bein, Multifunctional mesoporous silica nanoparticles as a universal platform for drug delivery. Chem. Mater. 26, 435–451 (2014). https://doi.org/10.1021/cm402592t
A. Schneemann, V. Bon, I. Schwedler, I. Senkovska, S. Kaskel, R.A. Fischer, Flexible metal–organic frameworks. Chem. Soc. Rev. 43, 6062–6096 (2014). https://doi.org/10.1039/C4CS00101J
J. Siefker, P. Karande, M.-O. Coppens, Packaging biological cargoes in mesoporous materials: opportunities for drug delivery. Expert Opin. Drug Deliv. 11, 1781–1793 (2014). https://doi.org/10.1517/17425247.2014.938636
Acknowledgements
This work was supported by the National Natural Science Foundation of China (Grant No. 21827811), Research and development plan of key areas in Hunan Province (Grant No. 2019SK2201), Innovation science and technology plan of Hunan Province (Grant No. 2017XK2103).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sun, Y., Zheng, L., Yang, Y. et al. Metal–Organic Framework Nanocarriers for Drug Delivery in Biomedical Applications. Nano-Micro Lett. 12, 103 (2020). https://doi.org/10.1007/s40820-020-00423-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40820-020-00423-3